Explore the words cloud of the NGN-PET project. It provides you a very rough idea of what is the project "NGN-PET" about.
The following table provides information about the project.
|Coordinator Country||Italy [IT]|
|Total cost||3˙050˙000 €|
|EC max contribution||1˙500˙000 € (49%)|
1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
|Duration (year-month-day)||from 2017-04-01 to 2020-03-31|
Take a look of project's partnership.
|1||AXXAM SPA||IT (BRESSO MILANO)||coordinator||450˙000.00|
|2||KING'S COLLEGE LONDON||UK (LONDON)||participant||450˙000.00|
|3||LIFE AND BRAIN GMBH||DE (BONN)||participant||450˙000.00|
|4||NATURWISSENSCHAFTLICHES UND MEDIZINISCHES INSTITUT AN DER UNIVERSITAET TUEBINGEN||DE (REUTLINGEN)||participant||150˙000.00|
|5||ESTEVE PHARMACEUTICALS, SA||ES (BARCELONA)||participant||0.00|
|6||GRUNENTHAL GMBH||DE (AACHEN)||participant||0.00|
Chronic Neuropathic Pain is frequently associated with peripheral nerve injury or disease. Peripheral injury activates both neuronal and glial components of the peripheral and central cellular circuitry. While it is widely known that the subsequently altered interactions between neurons and glial cells contribute to pain development and to its chronification, the underlying mechanisms are poorly understood. Developing mechanism-based therapies targeting neuron-glial interactions to treat chronic pain will be crucial for improving the quality of life of many patients. Hence the development of novel therapeutic solutions represents a major challenge that demands a multi-disciplinary approach to decipher and understand pathological mechanisms and to translate them into predictive tools for drug development. The NGN-PET consortium addresses this challenge by forming a highly interdisciplinary team that builds upon expertise in areas of academic research on pain mechanisms, industrial knowhow on human stem cell-based tool development, HTS technologies and drug discovery. To achieve its goal we will develop preclinical model systems and assays which recapitulate the human in vivo situation and which can be interrogated for the identification, validation of molecular targets and the development new treatments. A focus of the project will be chemotherapy induced NP and the interplay between nociceptors, microglia and Schwann cells. NGN-PET will carefully characterize rodent in vivo and in vitro models to identify these mechanisms, and will develop rat and human iPSCs based in vitro systems of neuron-glial co-cultures that can be interrogated for targets and used for compound identification and validation. NGN-PET will thus pose the basis for the translation of these model systems into high throughput screening platforms for pharmaceutical research and drug discovery.
|Interim dissemination and outreach report||Documents, reports||2020-04-08 22:25:47|
|Data Management Plan||Documents, reports||2020-04-08 22:25:47|
Take a look to the deliverables list in detail: detailed list of NGN-PET deliverables.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NGN-PET" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "NGN-PET" are provided by the European Opendata Portal: CORDIS opendata.
Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugsRead More
Bringing a prophylactic Ebola vaccine to licensureRead More
NOVEL GRAM-NEGATIVE ANTIBIOTIC NOWRead More